加载中
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
前收盘价
US$1.92
+US$0.11 · +6.08%
盘前
US$1.91
−US$0.01 · -0.52%
10月8日 9:14 ET
盘中时间采用ET。市场数据可能有所延迟。
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
日内区间
当前US$1.92
52周区间
当前US$1.92
盘中时间采用ET。市场数据可能有所延迟。
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
日内区间
当前US$1.92
52周区间
当前US$1.92
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2104.5万 USD | 1.01亿 USD | 9706.2万 USD | 1.34亿 USD | 2.07亿 USD |
| 销货成本 | 966.1万 USD | 1.86亿 USD | 884.8万 USD | — | 1.89亿 USD |
| 毛利 | 1138.4万 USD | −8538.2万 USD | 8821.4万 USD | 1.34亿 USD | 1767.8万 USD |
| 研究与开发 | 1.23亿 USD | 2.09亿 USD | 1.92亿 USD | 2.1亿 USD | 1.89亿 USD |
| 销售、一般及管理费用 | 5398.7万 USD | 5741万 USD | 5668.7万 USD | 6103.3万 USD | 5503.8万 USD |
| 营业费用 | 1.57亿 USD | 5961.5万 USD | 2.4亿 USD | 2.71亿 USD | 5503.8万 USD |
| 折旧和摊销 | 966.1万 USD | 884.1万 USD | 884.8万 USD | 847.2万 USD | 831.5万 USD |
| 营业利润 | −1.46亿 USD | −1.45亿 USD | −1.52亿 USD | −1.38亿 USD | −3736万 USD |
| 净利润 | −1.43亿 USD | −1.19亿 USD | −1.3亿 USD | −1.33亿 USD | −3632.9万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI641.37万0.00%2.3万亿 USD0.03%US$381.03-0.40%
iShares Russell 2000 ETFIWM467.4万0.01%785.63亿 USD0.19%US$277.7-1.29%
Vanguard Extended Market ETFVXF242.17万0.00%954亿 USD0.05%US$233.49-1.56%
iShares Russell 2000 Growth ETFIWO150.1万0.01%142.49亿 USD0.24%US$355.37-1.43%
Vanguard Russell 2000 ETFVTWO127.34万0.01%180亿 USD0.06%US$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA89.92万0.00%216.99亿 USD0.03%US$32.61-1.47%
Lazard Emerging Markets Opportunities ETFEMKT82.27万0.45%1.84亿 USD0.74%US$31.5798-1.20%
iShares Micro-Cap ETFIWC52.91万0.04%13.33亿 USD0.60%US$183.36-1.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHALazard Emerging Markets Opportunities ETFEMKTiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
